Literature DB >> 12588049

Polymorphism in intron 2 of islet amyloid polypeptide gene is associated with lower low-density lipoprotein cholesterol in nondiabetic subjects and in type 2 diabetic patients.

I Rojas1, R Gomis, E Casals, L I Quintó, C Franco, A Novials.   

Abstract

The aim of this study was to investigate the presence of mutations in the islet amyloid polypeptide (IAPP) gene in a Spanish population with type 2 diabetes and gestational diabetes mellitus (GDM). Using polymerase chain reaction single-stranded conformation polymorphism, we examined the coding region and the 5'-untranslated region (UTR) of the IAPP gene in 177 unrelated type 2 diabetic patients, 110 healthy control subjects, 38 women with GDM, and 38 gestational control subjects. Mutations were confirmed by DNA sequencing. A heterozygous C-to-A nucleotide substitution at +79 bp in intron 2 of the IAPP gene was detected. The frequencies of the +79-bp polymorphism (A allele) were 6.8% in type 2 diabetic patients, 7.7% in nondiabetic control subjects, 11.8% in women with GDM, and 9.2% in gestational control subjects. No AA genotypes were detected. Nondiabetic subjects and patients with type 2 diabetes bearing the CA genotype had lower low-density lipoprotein (LDL) cholesterol levels than subjects bearing wild genotype. Multivariate logistic regression analysis showed an independent association (p < 0.001; odds ratio: 0.33; 95% confidence interval: 0.17-0.63). We did not detect any sequence variant within exons 1 or 2. One diabetic patient was heterozygous for a silent mutation at codon 31 of exon 3 (Asn31 AAC --> AAT). Our findings indicate that the presence of the +79-bp polymorphism of the IAPP gene in nondiabetic subjects and in patients with type 2 diabetes is associated with lower levels of LDL cholesterol. Furthermore, abnormalities of the coding regions or the 5'-UTR of the IAPP gene are not associated with type 2 diabetes or GDM in the Spanish population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12588049     DOI: 10.1385/ENDO:19:2:185

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide.

Authors:  J Janson; W C Soeller; P C Roche; R T Nelson; A J Torchia; D K Kreutter; P C Butler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Role of S20G mutation of amylin gene in insulin secretion, insulin sensitivity, and type II diabetes mellitus in Taiwanese patients.

Authors:  L M Chuang; K C Lee; C N Huang; H P Wu; T Y Tai; B J Lin
Journal:  Diabetologia       Date:  1998-10       Impact factor: 10.122

3.  Missense mutation of amylin gene (S20G) in Japanese NIDDM patients.

Authors:  S Sakagashira; T Sanke; T Hanabusa; H Shimomura; S Ohagi; K Y Kumagaye; K Nakajima; K Nanjo
Journal:  Diabetes       Date:  1996-09       Impact factor: 9.461

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

6.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.

Authors:  G J Cooper; A C Willis; A Clark; R C Turner; R B Sim; K B Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

7.  Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients.

Authors:  M Nishi; G I Bell; D F Steiner
Journal:  Diabetologia       Date:  1990-10       Impact factor: 10.122

8.  Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects.

Authors:  A Clark; C A Edwards; L R Ostle; R Sutton; J B Rothbard; J F Morris; R C Turner
Journal:  Cell Tissue Res       Date:  1989-07       Impact factor: 5.249

9.  Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes.

Authors:  A Kautzky-Willer; K Thomaseth; B Ludvik; P Nowotny; D Rabensteiner; W Waldhäusl; G Pacini; R Prager
Journal:  Diabetes       Date:  1997-04       Impact factor: 9.461

10.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.

Authors:  A Lorenzo; B Razzaboni; G C Weir; B A Yankner
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

View more
  1 in total

1.  -To: Poa NR, Cooper GJS, Edgar PF: Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46: 574-578.

Authors:  A Novials; A Kistauri; A Chico; R Gomis
Journal:  Diabetologia       Date:  2003-11-05       Impact factor: 10.122

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.